PCR tests aim to identify and differentiate the Wuhan strain and Omicron variant of SARS-CoV-2. Credit: NIAID / Flickr.

Microbix Biosystems has introduced the new Omicron variant swab-formatted test control, expanding its portfolio of quality assessment products (QAPs).

The new test control helps to validate the integrity and accuracy of nucleic-acid based tests’ workflows for the SARS-CoV-2 Wuhan strain and Omicron variant.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The company is commercialising its in-vitro diagnostic (IVD) quality controls that can help to improve the workflow accuracy of clinical laboratory PCR tests, which aim to identify and differentiate the Wuhan strain and Omicron variant of SARS-CoV-2.

The Omicron QAP is developed using COPAN FLOQSwabs and is labelled as REDx FLOQ SARS-CoV-2 B.1.1.529 Swab Positive Control.

It offers a comprehensive and cost-effective quality management tool that helps avoid systemic errors made by consumables, technicians or instruments.

See Also:

Microbix Biosystems CEO and president Cameron Groome said: “For optimal patient care and public health management, clinicians and lab directors need controls that can provide them justifiable confidence in the accuracy and reliability of their testing programmes.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“Microbix’s suite of QAPs to support testing for respiratory pathogens is providing that essential support, driven by our ability to quickly respond to the emergence of new viruses or variants with pandemic-generating potential.

“We are pleased to add this Omicron-oriented QAP to maintain our complete coverage of all major Covid variants.”

The company stated that the QAP is currently available to support the quality management systems of clinical laboratories, covering central labs, as well as point-of care workflows in Canada and the US.

Last December, Microbix Biosystems introduced the new Multiplex Respiratory PCR-Test Control, which is branded as REDx FLOQ SARS-CoV-2/Flu A&B/RSV Swab Positive Control.